Close Menu

NEW YORK – Cancer diagnostic and vaccine startup Calviri said on Thursday that it has been awarded a $300,000 Phase I grant through the National Cancer Institute's Small Business Innovation Research Program, which will support the development of a new proteomic test for assessing whether a cancer patient’s tumor has high microsatellite instability.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.